secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001628280-23-005554
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma Q4 net loss $8.4M, revenue $48.4M; cash $710.3M
------------------------------------------------------------------

- Q4 2022 net loss $8.4M (vs $83.7M Q4 2021); full year net loss $183.1M (vs $250.2M).
- Revenue $48.4M in Q4 2022, up from $2.8M in Q4 2021, driven by GSK collaboration deferred revenue.
- Cash, cash equivalents and marketable securities $710.3M as of Dec 31, 2022; cash runway into 2026.
- Phase 1 trials ongoing for LYL797 (ROR1 CAR T) and LYL845 (TIL); initial data expected in 2024.
- Lynn Seely named President and CEO in Dec 2022; Rahsaan Thompson CLO; Gary Lee CSO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/0001628280-23-005554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/lyel-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-005554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer